Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $153.4152W HIGH $212.71
Volume
4.13 M
Value Traded
605.23 M
Short % Float
0.17%
Days to Cover
1.0
+4.95%Week
+3.56%1 Month
+1.43%3 Month
-8.24%6 Month
+64.22%5 Year
+368.75%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
266.85 B
EPS (TTM)
6.61
P/E Ratio
26.04
Ent. Value
301.56 B
Total Shares
1.55 B
Float Shares
1.50 B
Insiders
3.44%
Institutions
60.80%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
AZN Catalyst Timeline
Dated clinical, regulatory and corporate events for AstraZeneca PLC
Catalyst Timeline
Dated clinical, regulatory & corporate events for AstraZeneca PLC
143Total events
16Upcoming
90Tier-1 (high impact)
2023 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationPresentation
DESTINY-Breast11 MRI-assessed objective response data presented at ESMO 2026
HER2+ early breast cancersource ↗
◆Oral PresentationCapivasertibApprovedPresentation
CAPItello-281 updated overall survival data presented at ESMO 2026
PTEN-deficient metastatic hormone sensitive prostate cancersource ↗
▲Partnership / LicenseCorporate
insitro enters worldwide exclusive research collaboration with AstraZeneca for MASH and cardiomyopathies
MASH and cardiomyopathiessource ↗
▲Manufacturing MilestoneCMC / Inspection
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
▲Partnership / LicenseCorporate
Daiichi Sankyo and AstraZeneca enter clinical trial collaboration with Summit Therapeutics to evaluate Datroway plus ivonescimab
multiple tumor types including lung and breast cancerssource ↗
▲Milestone PaymentElecoglipronCorporate
Eccogene receives $50M milestone payment from AstraZeneca
▲Partnership / LicenseCorporate
Susan G. Komen and AstraZeneca announce Navigation Infrastructure Collaboration partnership
breast cancersource ↗
▲Partnership / LicenseZEGFROVYApprovedCorporate
AstraZeneca completes global license agreement with Dizal for ZEGFROVY (sunvozertinib)
lung cancersource ↗
▲Trial InitiationElecoglipronTrial
Initiation of Elevate Phase 3 outcome trials of elecoglipron in HFmrEF/HFpEF and CKD
heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and chronic kidney disease (CKD)source ↗
▲Partnership / LicenseZEGFROVYApprovedCorporate
Dizal grants AstraZeneca global exclusive license for Zegfrovy
non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutationssource ↗
●sNDA SubmissionZEGFROVYApprovedRegulatory Filing
sNDA submitted to China CDE for 1st-line indication
first-line NSCLC with EGFR exon20ins mutationssource ↗
▲Breakthrough Therapy DesignationZEGFROVYApprovedDesignation
Breakthrough Therapy Designation granted by China CDE
first-line NSCLC with EGFR exon20ins mutationssource ↗
▲FDA ApprovalZEGFROVYApprovedFDA Decision
Approved in US for 2nd-line NSCLC with EGFR exon20ins
locally advanced or metastatic NSCLC with EGFR exon20ins after platinum chemosource ↗
●sNDA SubmissionZEGFROVYApprovedRegulatory Filing
sNDA submitted to China CDE and US FDA for 1st-line setting
first-line NSCLC with EGFR exon20ins mutationssource ↗
▲Primary Endpoint MetImfinziApprovedClinical Data
Imfinzi VOLGA trial met primary endpoint in MIBC not candidates for cisplatin
MIBC not candidates for cisplatinsource ↗
▼Primary Endpoint MissedImfinziApprovedClinical Data
Imfinzi EMERALD-2 trial did not meet primary endpoint in adjuvant HCC
Adjuvant HCCsource ↗
▲Primary Endpoint Metsone-veClinical Data
sone-ve CLARITY-Gastric01 trial met primary endpoint in 2L+ Cldn18.2+ gastric/GEJ cancer
2L+ Cldn18.2+ gastric/GEJ cancersource ↗
▼Primary Endpoint MissedWainuaApprovedClinical Data
Wainua CARDIO-TTRansform trial did not meet primary endpoint in ATTR-CM
ATTR-CMsource ↗
▼Primary Endpoint MissedUltomirisApprovedClinical Data
Ultomiris TMA-313 trial did not meet primary endpoint in HSCT-TMA (adults)
HSCT-TMA (adults)source ↗
▲Primary Endpoint MetUltomirisApprovedClinical Data
Ultomiris ALXN1210-MG-319 trial met primary endpoint in paediatric gMG
gMG (paediatric)source ↗
▲FDA ApprovalCALQUENCEApprovedFDA Decision
Calquence approved in Japan for 1L CLL (fixed duration)
1L CLL (fixed duration)source ↗
▲FDA ApprovalDatrowayApprovedFDA Decision
Datroway approved in US for 1L TNBC where immunotherapy is not an option
1L TNBC for patients where immunotherapy is not an optionsource ↗
▲FDA ApprovalENHERTUApprovedFDA Decision
Enhertu approved in US for high-risk HER2+ early breast cancer (post-neoadjuvant)
High-risk HER2+ early breast cancer (post-neoadjuvant)source ↗
▲FDA ApprovalCamizestrantApprovedFDA Decision
Etcamah (camizestrant) approved in EU and Japan for ESR1m HR+ HER2- 1L locally advanced or metastatic breast cancer
ESR1m HR+ HER2- 1L locally advanced or metastatic breast cancersource ↗
▲FDA ApprovalImfinziApprovedFDA Decision
Imfinzi approved in Japan for resectable gastric/GEJ cancer
Resectable gastric/GEJ cancersource ↗
▲FDA ApprovalOrphathysApprovedFDA Decision
Orphathys approved in China for 3L+ MET+ gastric/GEJ cancer
3L+ MET+ gastric/GEJ cancersource ↗
▲FDA ApprovalTRUQAPApprovedFDA Decision
Truqap approved in US for PTEN-deficient mHSPC
PTEN-deficient mHSPCsource ↗
▲FDA ApprovalBaxfendyApprovedFDA Decision
Baxfendy approved in US for hypertension
Hypertensionsource ↗
▲FDA ApprovalFasenraApprovedFDA Decision
Fasenra approved in US, EU, Japan and China for hypereosinophilic syndrome
Hypereosinophilic syndromesource ↗
▲FDA Filing AcceptedBaxfendyApprovedRegulatory Filing
Baxfendy regulatory submission accepted in Japan for hypertension
Hypertensionsource ↗
▲FDA Filing AcceptedTozorakimabFiledRegulatory Filing
tozorakimab regulatory submission accepted in EU and China for COPD
COPDsource ↗
▲FDA Filing AcceptedUltomirisApprovedRegulatory Filing
Ultomiris regulatory submission accepted in US and Japan for IgAN
IgANsource ↗
▲FDA Filing Acceptedefzimfotase alfaFiledRegulatory Filing
efzimfotase alfa regulatory submission accepted in Japan for HPP
HPPsource ↗
▲Partnership / LicenseZEGFROVYApprovedCorporate
AstraZeneca entered exclusive license agreement with Dizal for Zegfrovy (sunvozertinib)
lung cancersource ↗
▲Partnership / LicenseTQC3721Corporate
AstraZeneca and CTTQ entered exclusive licence agreement for TQC3721
respiratory indicationssource ↗
◆PDUFA DateDatrowayApprovedRegulatory Filing
PDUFA date set for DATROWAY sBLA in TNBC
metastatic triple negative breast cancersource ↗
▲Late-BreakerZEGFROVYApprovedPresentation
Late-Breaking Abstract Oral Presentation at 2026 ASCO and NEJM publication
first-line NSCLC with EGFR exon20ins mutationssource ↗
▲Oral PresentationZEGFROVYApprovedPresentation
Late-Breaking Abstract Oral Presentation at 2026 ASCO Annual Meeting
first-line NSCLC with EGFR exon20ins mutationssource ↗
▲PublicationZEGFROVYApprovedPresentation
WU-KONG28 results published in New England Journal of Medicine
first-line NSCLC with EGFR exon20ins mutationssource ↗
▲FDA ApprovalDatrowayApprovedFDA Decision
Datroway approved in U.S. for first-line treatment of metastatic triple negative breast cancer in patients not candidates for PD-1/PD-L1 inhibitors
metastatic triple negative breast cancersource ↗
▲IND ClearancelumipodlinIND
IND cleared by NMPA for lumipodlin + Tagrisso combination study
EGFR-mutated PD-L1 positive locally advanced or metastatic NSCLCsource ↗
◆PDUFA DateENHERTUApprovedRegulatory Filing
PDUFA date of May 18, 2026 for neoadjuvant sBLA
HER2 positive stage 2 or stage 3 breast cancer (neoadjuvant)source ↗
▲AdCom OutcomeTRUQAPApprovedAdvisory Committee
ODAC voted 7-1-1 that TRUQAP plus abiraterone and ADT has favorable benefit-risk profile
PTEN-deficient metastatic hormone-sensitive prostate cancersource ↗
◆PDUFA DateDatrowayApprovedRegulatory Filing
PDUFA date set for Q2 2026
metastatic triple-negative breast cancer (TNBC)source ↗
▲Partnership / LicensePTX-299Corporate
AstraZeneca exercised option for exclusive global license to PTX-299 from Pinetree
▲Partnership / LicenseCorporate
AstraZeneca closed strategic collaboration with CSPC for next-generation obesity and T2D therapies
obesity and type 2 diabetessource ↗
▲Primary Endpoint MetImfinziApprovedClinical Data
Imfinzi EMERALD-3 met primary endpoint in locoregional HCC
Locoregional HCCsource ↗
Past FDA Catalysts and PDUFA Decisions
How AZN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-25 | IMFINZI combinations with datopotamab deruxtecan (DATROWAY), oleclumab and monalizumab | Phase 2 data presentation | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
149
Drugs Scored
rNPV / MCap
Top Drug
Top 1%
Large Pharma(rank 8 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (20-F and 6-K), to Jun 2026; product lines: last four quarters to Jun 2026 (20-F and 6-K))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Farxiga | |||
| Tagrisso | |||
| Imfinzi | |||
| Ultomiris | |||
| Calquence | |||
| Lynparza | |||
| Symbicort | |||
| Fasenra | |||
| Strensiq | |||
| Soliris | |||
| Breztri | |||
| Crestor |
Top 12 of 30 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Elecoglipron Small moleculeNCT07662044 | Type 2 Diabetes Mellitus | Phase 3 | RECRUITING | 5,500 | Jul 14, 2028 | ||||||
| Elecoglipron Small moleculeNCT07667803 | Weight Management | Phase 3 | RECRUITING | 4,500 | Jul 30, 2029 | ||||||
| Elecoglipron Small moleculeNCT07775404 | Obesity | Phase 3 | RECRUITING | 351 | Apr 13, 2028 | ||||||
| Elecoglipron Small moleculeNCT07753993 | Chronic Kidney Disease | Phase 3 | RECRUITING | 7,000 | Oct 4, 2030 | ||||||
| Elecoglipron Small moleculeNCT07761117 | Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 3 | RECRUITING | 6,950 | Sep 3, 2029 | ||||||
| Datopotamab deruxtecan ADCNCT05687266 | NSCLC | Phase 3 | ACTIVE NOT_RECRUITING | 1,350 | Nov 1, 2027 | ||||||
| Dato-DXd ADCNCT06417814 | Metastatic Non-small Cell Lung Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 768 | Sep 27, 2028 | ||||||
| Datopotamab deruxtecan ADCNCT05215340 | Metastatic Non Small Cell Lung Cancer | Phase 3 | RECRUITING | 740 | Apr 30, 2028 | ||||||
| Dato-DXd ADCNCT07720284 | High-risk Muscle Invasive Urothelial Carcinoma | Phase 3 | RECRUITING | 915 | Nov 23, 2032 | ||||||
| Datopotamab deruxtecan ADCNCT06564844 | Non-small Cell Lung Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 1,100 | Mar 31, 2027 | ||||||
| Datopotamab deruxtecan ADCMarketedNCT07069595 | Breast Cancer | Phase 2 | RECRUITING | 78 | Nov 1, 2032 | ||||||
| Datopotamab deruxtecan ADCNCT05489211 | Endometrial Cancer | Phase 2 | RECRUITING | 454 | Oct 1, 2027 | ||||||
| Dato-DXd ADCNCT07129993 | Urothelial Cancer | Phase 2 | RECRUITING | 630 | Jan 22, 2030 | ||||||
| Datopotamab deruxtecan ADCNCT05460273 | Carcinoma, Non-Small-Cell Lung | Phase 1 | ACTIVE NOT_RECRUITING | 119 | Jun 30, 2027 | ||||||
| Datopotamab deruxtecan ADCNCT04612751 | Advanced or Metastatic NSCLC | Phase 1 | ACTIVE NOT_RECRUITING | 155 | May 4, 2027 | ||||||
| AZD0780 Small moleculeNCT07000136 | Heterozygous Familial Hypercholesterolaemia | Phase 3 | ACTIVE NOT_RECRUITING | 473 | Jan 4, 2027 | ||||||
| Laroprovstat Small moleculeNCT07619118 | Hypercholesterolaemia | Phase 3 | RECRUITING | 800 | May 28, 2027 | ||||||
| AZD0780 Small moleculeNCT07000123 | Cardiovascular Disease | Phase 3 | ACTIVE NOT_RECRUITING | 18,211 | Jan 11, 2027 | ||||||
| Rilvegostomig Monoclonal antibodyNCT06868277 | Carcinoma, Non-Small Cell Lung | Phase 3 | RECRUITING | 830 | Dec 2, 2030 | ||||||
| Volrustomig Monoclonal antibodyNCT06943833 | Locally Advanced Cervical Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 837 | Mar 13, 2029 | ||||||
| Volrustomig Small moleculeNCT05984277 | Metastatic Non-small Cell Lung Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 895 | Nov 12, 2027 | ||||||
| Rilvegostomig Small moleculeNCT06627647 | Non-squamous Non-small Cell Lung Cancer | Phase 3 | RECRUITING | 1,160 | Nov 18, 2030 | ||||||
| Rilvegostomig Small moleculeNCT07098338 | Non-Small Cell Lung Cancer | Phase 3 | RECRUITING | 1,438 | Apr 6, 2029 | ||||||
| Rilvegostomig Small moleculeNCT06764875 | HER2-positive Gastric Cancer | Phase 3 | RECRUITING | 840 | Dec 9, 2030 | ||||||
| Saruparib Small moleculeNCT06380751 | Advanced Breast Cancer | Phase 3 | RECRUITING | 788 | Dec 30, 2031 |
Clinical Trial Results
Readouts, endpoints and source filings for every AZN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Sone-Ve | CLDN18.2-positive gastric cancer | Phase 3 | 2026-10-19 | statistically significant and clinically meaningful overall survival (OS) benefitRead More | AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinibRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sharma ManiOfficer (See Remarks) | Buy | 20.233 19,287.699 held | $160.57 | 08/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AZN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 3.2 % (23.1 %) | 171.08 M | 915.70 K | 36.63% ( 245.50 K) |
AZN Institutional Ownership Trends
AZN Short Interest
Shares sold short, counted twice a month.
0.17%
Short % of Float
of tradable shares sold short
2.6M
Shares Sold Short
+25.4% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
2.8M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AZN ranks across every disease it competes in
Competitive Position is a premium feature
See how AZN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAZN News
AZNAstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib
AstraZeneca will present pivotal Phase III trial data at the ESMO Congress 2026, showcasing promising results for several cancer treatments. Key highlights include the CLARITY-Gastric01 trial of Sone-Ve, which shows significant overall survival benefits for gastric cancer patients, and the SAFFRON trial, demonstrating the efficacy of TAGRISSO combined with savolitinib for lung cancer. The findings suggest a transformative potential for combination therapies in improving patient outcomes across various cancer types.
Read more →AZNinsitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies
insitro has entered a strategic collaboration with AstraZeneca to leverage its AI platform for discovering new therapeutics targeting metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. The agreement includes an upfront payment of $40 million and potential milestones totaling approximately $1.46 billion. AstraZeneca will oversee clinical development and commercialization, aiming to address the complexities of these underdiagnosed diseases.
Read more →AZNAstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
AstraZeneca has inaugurated a new global strategic R&D center in Kendall Square, Cambridge, Massachusetts. This facility strengthens the company's existing presence in the area and aims to foster innovation by placing scientists in a leading life sciences ecosystem. The center is expected to enhance collaboration in genomic medicine and other research areas.
Read more →AZNDaiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
Daiichi Sankyo and AstraZeneca have formed a clinical trial collaboration with Summit Therapeutics to assess the efficacy of Datroway® in combination with ivonescimab across various tumor types, including lung and breast cancers. The collaboration will commence with a phase 3 trial focusing on first-line treatment for triple negative breast cancer. This partnership aims to enhance treatment options for patients with these cancers.
Read more →AZNEccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004)
Eccogene has received a $50 million milestone payment from AstraZeneca following the initiation of a Global Phase 3 program for Elecoglipron (AZD5004/ECC5004). This payment marks a significant step in the development of the drug, showcasing the partnership's progress. The Phase 3 program is crucial for the drug's potential approval and market entry.
Read more →AZNPolaris Rx Named Exclusive U.S. Distributor of AstraZeneca's FluMist® Home Service for Second Consecutive Year
Polaris Rx has been named the exclusive U.S. distributor for AstraZeneca's FluMist Home service for the 2026-2027 flu season, marking the second consecutive year of this partnership. This service allows individuals to conveniently order the flu vaccine online and have it delivered directly to their homes. The collaboration aims to improve access to flu vaccinations.
Read more →AZNSusan G. Komen® and AstraZeneca Partnership to Make Patient Navigation Available to All
Susan G. Komen has partnered with AstraZeneca to enhance patient navigation in breast cancer care. This initiative aims to integrate patient navigation into the national healthcare system, addressing barriers and improving access to timely treatments. The collaboration seeks to reduce patient stress and enhance adherence to cancer care plans across the nation.
Read more →AZNAstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer
AstraZeneca has finalized a global license agreement with Dizal Pharmaceutical for ZEGFROVY (sunvozertinib), an oral EGFR inhibitor for lung cancer. This agreement grants AstraZeneca worldwide rights to develop and commercialize the drug, which is already approved in the US and China for second-line treatment in adults.
Read more →AZNAstraZeneca results: H1 and Q2 2026
AstraZeneca reported strong financial results for H1 2026, with total revenue increasing by 9% compared to the previous year. Product sales reached $28.9 billion, reflecting an 8% growth. The company's core EPS also showed a positive trend, rising by 12%. However, collaboration revenue experienced a decline of 6%. Overall, the results indicate a solid performance despite some challenges.
Read more →AZNDizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy
Dizal has entered a global exclusive license agreement with AstraZeneca for Zegfrovy, an EGFR inhibitor for lung cancer. The deal includes a $600M upfront payment and potential milestone payments of up to $900M. Zegfrovy is already approved in China and the US for treating advanced NSCLC with specific mutations. AstraZeneca aims to leverage its oncology expertise to expand Zegfrovy's reach.
Read more →AZNHelix Announces Multi-Year Agreement with AstraZeneca to Support Genomic Research for Drug Discovery and Development
Helix has entered a multi-year agreement with AstraZeneca to provide access to its GenoSphere cohorts, which include extensive genomic and clinical data. This collaboration aims to enhance drug discovery and development by leveraging integrated clinico-genomic data. The partnership is expected to accelerate biomedical research and improve the development of targeted therapies.
Read more →AZN▲ +6.1%on this newsshared move
Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
Abbisko Therapeutics has partnered with AstraZeneca to conduct a Phase I/II clinical trial for lumipodlin (ABSK043), an oral PD-L1 inhibitor, in combination with TAGRISSO® for treating non-small cell lung cancer (NSCLC). The trial aims to evaluate the safety and efficacy of this novel therapy for patients with EGFR mutations and high PD-L1 expression. The IND application for the study was recently approved by the National Medical Products Administration.
Read more →AZNAstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
AstraZeneca has formed a partnership with YMCA of the USA to tackle disparities in cancer care. This collaboration aims to enhance accessibility and improve health outcomes for communities. The initiative is expected to address critical gaps in healthcare services related to cancer treatment and support.
Read more →AZNLung Cancer Research Foundation and AstraZeneca Announce Open Call for Research Proposals with Focus on Small Cell Lung Cancer
The Lung Cancer Research Foundation and AstraZeneca have announced two research awards aimed at improving treatment outcomes for small cell lung cancer (SCLC). The awards, totaling $750,000, will support innovative strategies and patient advocacy efforts. Submissions for research proposals are open until July 15, 2026, with the goal of advancing understanding and treatment of this challenging cancer.
Read more →AZNDatroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
Datroway® has received U.S. approval as the first TROP2 directed antibody drug conjugate. It is intended for first-line treatment of patients with metastatic triple negative breast cancer who are not eligible for PD-1/PD-L1 inhibitors. This approval marks a significant advancement in treatment options for this patient population.
Read more →AZNAstraZeneca Collaborates with Roche Diagnostics Asia Pacific to Help Accelerate Sustainable Ecosystem for Advanced Pathology in Breast and Lung Cancer
AstraZeneca and Roche Diagnostics Asia Pacific have entered a three-year Memorandum of Understanding to enhance digital pathology capabilities across nine Asian markets. This collaboration aims to improve biomarker testing for breast and lung cancer through AI-powered solutions and educational initiatives. The partnership addresses significant gaps in diagnostic processes and aims to standardize and improve cancer care.
Read more →AZNTRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
The FDA's Oncologic Drugs Advisory Committee has recommended AstraZeneca's TRUQAP (capivasertib) in combination with abiraterone and ADT for PTEN-deficient metastatic hormone-sensitive prostate cancer. This recommendation is based on favorable results from the CAPItello-281 Phase III trial, which demonstrated a significant reduction in disease progression. The treatment addresses a critical need for patients with limited options and is the first targeted therapy for this cancer subtype.
Read more →AZNKoselugo approved in Canada for plexiform neurofibromas in adults with neurofibromatosis type 1
Koselugo (selumetinib) has been approved in Canada for adults with neurofibromatosis type 1 (NF1) suffering from symptomatic, inoperable plexiform neurofibromas. This approval follows positive results from the KOMET Phase III trial, which showed a 20% objective response rate in tumor size reduction. Experts highlight the significance of this treatment option for patients who previously had limited therapeutic choices.
Read more →AZNENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
AstraZeneca and Daiichi Sankyo's ENHERTU has received Priority Review from the FDA for treating HER2 positive early breast cancer patients with residual disease after neoadjuvant therapy. The decision follows promising results from the DESTINY-Breast05 trial, which demonstrated a significant reduction in disease recurrence. The FDA's target action date for this application is July 7, 2026.
Read more →AZNSECURITIES AND EXCHANGE COMMISSION
AstraZeneca PLC has filed a report with the SEC for February 2026, according to the requirements set forth by the Securities Exchange Act of 1934. The filing includes details about the registrant’s annual financial report and compliance with various regulatory requirements. This follows standard practice for foreign issuers under SEC regulations.
Read more →About AstraZeneca PLC
HeadquartersCambridge
Founded1913
BIOPHARMAWATCH ELITE PLUS
Trade the next AZN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime